Lu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lu Wang has a total of 330 co-authors. Here are the top co-authors by number of shared publications:
- Marc Ladanyi
Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine New York, New York
12 shared publications - Helena Alexandra Yu
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
11 shared publications - Jorge Sergio Reis-Filho
Department of Pathology and Laboratory Medicine Memorial Sloan Kettering Cancer Center New York NY USA
11 shared publications - Alvaro Quintanal-Villalonga
Memorial Sloan Kettering Cancer Center
10 shared publications - Andre L. Moreira
Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY
10 shared publications - Anita S. Bowman
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
10 shared publications
Latest Publications
- 25 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6489-6500
Outcomes of germ line testing for children with hematologic malignancies undergoing hematopoietic cell transplantation
Recent studies reveal that a growing proportion of children with hematologic malignancies (HM) harbor germ line pathogenic or likely pathogenic variants (PV) in cancer-predisposing genes (CPG). Identifying these children is critical because the information gained guides leukemia therapy, family testing, and selection of related donors for hematopoietic cell transplantation (HCT). Nevertheless, it remains unclear how often children with HM being considered for HCT undergo genetic evaluation and whether germ line data are used to guide clinical practice. To address this gap, we reviewed the records of 286 children who underwent ≥1 HCT for HM at St. Jude Children's Research Hospital between 1 January 2017 and 31 December 2023. We examined the timeline of genetic evaluation, prevalence of germ line PV, and impact of PV on HCT outcomes. Overall, 227 (79%) children met with a genetic counselor before their first HCT, 192 underwent testing, and 142 had results returned before the HCT. Thirty-six patients (19%) harbored a germ line CPG PV, among whom 12 (6%) had PV aligning with their HM diagnosis. Of 5 patients who received an HCT from a PV-positive relative, 1 patient developed donor-derived leukemia. We observed no significant differences in time to neutrophil engraftment, cumulative incidence of relapse, or overall survival between patients with and without PV, although the cohort was heterogeneous with respect to the underlying PV. Given the high prevalence of PV in children with HM, prompt referral to genetics is warranted to ensure timely counseling and germ line testing to detect a hereditary predisposition and inform donor selection for HCT.
- 25 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6489-6500
Outcomes of germ line testing for children with hematologic malignancies undergoing hematopoietic cell transplantation
Recent studies reveal that a growing proportion of children with hematologic malignancies (HM) harbor germ line pathogenic or likely pathogenic variants (PV) in cancer-predisposing genes (CPG). Identifying these children is critical because the information gained guides leukemia therapy, family testing, and selection of related donors for hematopoietic cell transplantation (HCT). Nevertheless, it remains unclear how often children with HM being considered for HCT undergo genetic evaluation and whether germ line data are used to guide clinical practice. To address this gap, we reviewed the records of 286 children who underwent ≥1 HCT for HM at St. Jude Children's Research Hospital between 1 January 2017 and 31 December 2023. We examined the timeline of genetic evaluation, prevalence of germ line PV, and impact of PV on HCT outcomes. Overall, 227 (79%) children met with a genetic counselor before their first HCT, 192 underwent testing, and 142 had results returned before the HCT. Thirty-six patients (19%) harbored a germ line CPG PV, among whom 12 (6%) had PV aligning with their HM diagnosis. Of 5 patients who received an HCT from a PV-positive relative, 1 patient developed donor-derived leukemia. We observed no significant differences in time to neutrophil engraftment, cumulative incidence of relapse, or overall survival between patients with and without PV, although the cohort was heterogeneous with respect to the underlying PV. Given the high prevalence of PV in children with HM, prompt referral to genetics is warranted to ensure timely counseling and germ line testing to detect a hereditary predisposition and inform donor selection for HCT.
- Open Access
- 23 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy
- 23 April 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
Open AccessNovel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy
- Open Access
Clonal Evolution of Pediatric Acute Myeloid Leukemia and Its Contribution to Disease Relapse
Relapse remains the leading cause of mortality in pediatric acute myeloid leukemia (AML), yet the genetic changes contributing to relapse remain incompletely defined. To address this gap, we performed whole-genome sequencing and targeted-capture sequencing on 39 diagnosis–relapse and 2 relapse–relapse pairs of pediatric AML. Mutational burden increased at relapse, largely reflecting spontaneous mutagenesis, whereas therapy-related signatures were rarely observed and only occasionally associated with pathogenic mutations. Although recurrently enriched mutations at relapse included those in FLT3 , WT1 , and TP53 , relapse-fated subclones were frequently marked only by non-pathogenic or non-coding variants. Longitudinal deep sequencing in eight patients showed rapid depletion of major clones after induction therapy, whereas subclones often displayed variable chemosensitivity. Relapse-specific mutations emerged only late or remained undetectable during remission, suggesting that clonal selection of pre-existing clones is the predominant mechanism of relapse. Transcriptome analysis of paired RNA sequencing data revealed no differentially expressed genes, but gene set enrichment analysis and CIBERSORT deconvolution in each pair uncovered heterogeneous trajectories to relapse. Although relapse is often attributed to the emergence of stem-like phenotypes, our data demonstrate that transcriptional evolution is more diverse: some cases acquired stem-like features, whereas others showed partial differentiation, which was confirmed by re-analysis of a public single cell RNA sequence dataset. These changes were largely constrained by baseline differentiation states at diagnosis. Together, our data indicate that pediatric AML relapse arises through selection of pre-existing clones with diverse trajectories, underscoring the need to target both stem-like and differentiated populations to achieve durable cures.
Open AccessClonal Evolution of Pediatric Acute Myeloid Leukemia and Its Contribution to Disease Relapse
Relapse remains the leading cause of mortality in pediatric acute myeloid leukemia (AML), yet the genetic changes contributing to relapse remain incompletely defined. To address this gap, we performed whole-genome sequencing and targeted-capture sequencing on 39 diagnosis–relapse and 2 relapse–relapse pairs of pediatric AML. Mutational burden increased at relapse, largely reflecting spontaneous mutagenesis, whereas therapy-related signatures were rarely observed and only occasionally associated with pathogenic mutations. Although recurrently enriched mutations at relapse included those in FLT3 , WT1 , and TP53 , relapse-fated subclones were frequently marked only by non-pathogenic or non-coding variants. Longitudinal deep sequencing in eight patients showed rapid depletion of major clones after induction therapy, whereas subclones often displayed variable chemosensitivity. Relapse-specific mutations emerged only late or remained undetectable during remission, suggesting that clonal selection of pre-existing clones is the predominant mechanism of relapse. Transcriptome analysis of paired RNA sequencing data revealed no differentially expressed genes, but gene set enrichment analysis and CIBERSORT deconvolution in each pair uncovered heterogeneous trajectories to relapse. Although relapse is often attributed to the emergence of stem-like phenotypes, our data demonstrate that transcriptional evolution is more diverse: some cases acquired stem-like features, whereas others showed partial differentiation, which was confirmed by re-analysis of a public single cell RNA sequence dataset. These changes were largely constrained by baseline differentiation states at diagnosis. Together, our data indicate that pediatric AML relapse arises through selection of pre-existing clones with diverse trajectories, underscoring the need to target both stem-like and differentiated populations to achieve durable cures.
- 31 October 2025
- Published by Cassyni
Clinical Experience of Using Integrated Whole Genome and Transcriptome Sequencing as A Framework for Pediatric and Adolescent Acute Myeloid Leukemia Diagnosis and Risk Assessment
Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic implications. Cytogenetics study, along with Next Generation Sequencing (NGS) panel testing, have long been the standard for molecular diagnosis of AML. While these approaches enable diagnosis and prognosis determination in most cases, they have limitations—particularly in detecting emerging rare, recurrent genetic abnormalities. In this study, we systematically reviewed our real-time clinical experience with the diagnostic workup of pediatric AML using an integrated whole genome and whole transcriptome sequencing (iWGS-WTS) approach and compared the test results obtained from various methodologies, including whole genome sequencing (WGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS), iWGS-WTS, cytogenetics, and targeted panel NGS. Our findings demonstrate that the iWGS-WTS approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Additionally, the iWGS-WTS approach streamlines sample acquisition and reduces testing redundancy, positioning it as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.
- 31 October 2025
- Published by Cassyni
Clinical Experience of Using Integrated Whole Genome and Transcriptome Sequencing as A Framework for Pediatric and Adolescent Acute Myeloid Leukemia Diagnosis and Risk Assessment
Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic implications. Cytogenetics study, along with Next Generation Sequencing (NGS) panel testing, have long been the standard for molecular diagnosis of AML. While these approaches enable diagnosis and prognosis determination in most cases, they have limitations—particularly in detecting emerging rare, recurrent genetic abnormalities. In this study, we systematically reviewed our real-time clinical experience with the diagnostic workup of pediatric AML using an integrated whole genome and whole transcriptome sequencing (iWGS-WTS) approach and compared the test results obtained from various methodologies, including whole genome sequencing (WGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS), iWGS-WTS, cytogenetics, and targeted panel NGS. Our findings demonstrate that the iWGS-WTS approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Additionally, the iWGS-WTS approach streamlines sample acquisition and reduces testing redundancy, positioning it as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.
- Open Access
- 7 October 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (12) , 2946-2956
Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment
Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic implications. Cytogenetics study, along with Next Generation Sequencing (NGS) panel testing, have long been the standard for molecular diagnosis of AML. While these approaches enable diagnosis and prognosis determination in most cases, they have limitations—particularly in detecting emerging rare, recurrent genetic abnormalities. In this study, we systematically reviewed our real-time clinical experience with the diagnostic workup of pediatric AML using an integrated whole genome and whole transcriptome sequencing (iWGS-WTS) approach and compared the test results obtained from various methodologies, including whole genome sequencing (WGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS), iWGS-WTS, cytogenetics, and targeted panel NGS. Our findings demonstrate that the iWGS-WTS approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Additionally, the iWGS-WTS approach streamlines sample acquisition and reduces testing redundancy, positioning it as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.
- 7 October 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (12) , 2946-2956
Open AccessClinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment
Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic implications. Cytogenetics study, along with Next Generation Sequencing (NGS) panel testing, have long been the standard for molecular diagnosis of AML. While these approaches enable diagnosis and prognosis determination in most cases, they have limitations—particularly in detecting emerging rare, recurrent genetic abnormalities. In this study, we systematically reviewed our real-time clinical experience with the diagnostic workup of pediatric AML using an integrated whole genome and whole transcriptome sequencing (iWGS-WTS) approach and compared the test results obtained from various methodologies, including whole genome sequencing (WGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS), iWGS-WTS, cytogenetics, and targeted panel NGS. Our findings demonstrate that the iWGS-WTS approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Additionally, the iWGS-WTS approach streamlines sample acquisition and reduces testing redundancy, positioning it as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.
- Open Access
- 10 March 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (2)
Genomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- 10 March 2025
- Published by Elsevier in Blood Neoplasia
- Vol. 2 (2)
Open AccessGenomic landscape and clonal architecture in pediatric myeloid neoplasms with chromosome 7 deletions
- Open Access
- 22 January 2025
- Published by Springer Nature in Research Square
Integrated Whole Genome and Transcriptome Sequencing as a Framework for Pediatric and Adolescent AML Diagnosis and Risk Assessment
Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic significance. Emerging rare, recurrent genetic abnormalities and their associations with outcomes emphasize the need for high-throughput molecular diagnostic tools. Whole genome sequencing (WGS) reliably detects key AML biomarkers such as structural variants, mutations, and copy number alterations. Whole transcriptome sequencing (WTS) complements WGS by uncovering oncogene expression patterns, allele-specific expression, and gene expression signatures. In this study, we describe an integrated WGS and WTS clinical workflow for routine pediatric AML diagnosis and present a systematic evaluation of its application compared to conventional cytogenetics and standard molecular diagnostic methods. Our findings demonstrate that the integrated WGS and WTS (iWGS-WTS) approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Moreover, with advancements in workflow and bioinformatics pipelines, the testing turnaround time can be optimized to meet the demands of clinical decision-making, positioning iWGS-WTS as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.
- 22 January 2025
- Published by Springer Nature in Research Square
Open AccessIntegrated Whole Genome and Transcriptome Sequencing as a Framework for Pediatric and Adolescent AML Diagnosis and Risk Assessment
Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic significance. Emerging rare, recurrent genetic abnormalities and their associations with outcomes emphasize the need for high-throughput molecular diagnostic tools. Whole genome sequencing (WGS) reliably detects key AML biomarkers such as structural variants, mutations, and copy number alterations. Whole transcriptome sequencing (WTS) complements WGS by uncovering oncogene expression patterns, allele-specific expression, and gene expression signatures. In this study, we describe an integrated WGS and WTS clinical workflow for routine pediatric AML diagnosis and present a systematic evaluation of its application compared to conventional cytogenetics and standard molecular diagnostic methods. Our findings demonstrate that the integrated WGS and WTS (iWGS-WTS) approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Moreover, with advancements in workflow and bioinformatics pipelines, the testing turnaround time can be optimized to meet the demands of clinical decision-making, positioning iWGS-WTS as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Cohort selection and clinicopathologic characteristics. A, Schematic diagram of RB1 and TP53 inactivation (outer doughnut) and smoking status (inner doughnut) in a cohort of 600 consecutive SCLC that underwent tNGS by MSK-IMPACT. RB1 and TP53 status was determined based on integrated genomic and IHC data (see “Results”). B, Tabular and (C) pictorial summary of pathologic sample characteristics and sequencing assays performed for 20 patients with aSCLC. See “Methods” for histopathologic criteria. Ki67 not available. D, Summary of metastatic site distribution based on radiologic–pathologic findings (full data in Supplementary Table S2). E–G, Compilation of radiologic and pathologic findings for three representative patients. E, (A01): 19-year-old patient with brain metastasis showing classic undifferentiated morphology of SCLC: small, crowded/molding cells, numerous mitotic figures (>50/2 mm2), apoptotic bodies, and Ki67 of 90%, whereas thoracic sample shows well-differentiated, nested morphology of a carcinoid tumor lacking mitotic figures or apoptotic bodies, and exhibiting Ki67 of 5%–20%. F, Case A08 and (G) case A09 illustrate classic SCLC morphology in primary lung tumor samples, featuring Ki67 rate of 80% and 90%, respectively. n indicates areas of extensive necrosis–a hallmark feature of SCLC. For extended pathologic illustrations, see Supplementary Figs. S1–S4. Scale bars are 100 μm for Ki67 and 50 μm for H&E except for top in F which is 1 mm. H, Comparison of age, Ki67 proliferation index, and smoking pack-years in aSCLC vs. other SCLC (n = 224 for age and Ki67; n = 200 for pack-year smoking). For patients with multiple samples, Ki67 represents the maximal (max) hot-spot rate among all evaluated samples. H&E, hematoxylin and eosin; FNA, fine needle aspiration; Core bx, core biopsy; py, pack-years; tNGS, targeted next-generation sequencing. (C, D created in part with BioRender.com.)
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Cohort selection and clinicopathologic characteristics. A, Schematic diagram of RB1 and TP53 inactivation (outer doughnut) and smoking status (inner doughnut) in a cohort of 600 consecutive SCLC that underwent tNGS by MSK-IMPACT. RB1 and TP53 status was determined based on integrated genomic and IHC data (see “Results”). B, Tabular and (C) pictorial summary of pathologic sample characteristics and sequencing assays performed for 20 patients with aSCLC. See “Methods” for histopathologic criteria. Ki67 not available. D, Summary of metastatic site distribution based on radiologic–pathologic findings (full data in Supplementary Table S2). E–G, Compilation of radiologic and pathologic findings for three representative patients. E, (A01): 19-year-old patient with brain metastasis showing classic undifferentiated morphology of SCLC: small, crowded/molding cells, numerous mitotic figures (>50/2 mm2), apoptotic bodies, and Ki67 of 90%, whereas thoracic sample shows well-differentiated, nested morphology of a carcinoid tumor lacking mitotic figures or apoptotic bodies, and exhibiting Ki67 of 5%–20%. F, Case A08 and (G) case A09 illustrate classic SCLC morphology in primary lung tumor samples, featuring Ki67 rate of 80% and 90%, respectively. n indicates areas of extensive necrosis–a hallmark feature of SCLC. For extended pathologic illustrations, see Supplementary Figs. S1–S4. Scale bars are 100 μm for Ki67 and 50 μm for H&E except for top in F which is 1 mm. H, Comparison of age, Ki67 proliferation index, and smoking pack-years in aSCLC vs. other SCLC (n = 224 for age and Ki67; n = 200 for pack-year smoking). For patients with multiple samples, Ki67 represents the maximal (max) hot-spot rate among all evaluated samples. H&E, hematoxylin and eosin; FNA, fine needle aspiration; Core bx, core biopsy; py, pack-years; tNGS, targeted next-generation sequencing. (C, D created in part with BioRender.com.)
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Multisample analysis from all temporally or spatially distinct samples obtained for each patient. A, Conservation of chromothripsis and corresponding amplifications across all samples with available data from individual patients. ^ indicates lower purity samples compared with the other sample from same patient (Supplementary Table S5); CN values in such samples may be falsely low. * indicates chromothripsis detected by WGS only, but not detected by tNGS. N/A, not available: sample without NGS or IHC. Sample numbering is chronologic (Supplementary Table S3). B, Multisample analysis showing RB1 and TP53 genomic alterations and expression of pRb, p53, and p16 by IHC, illustrating a subset of patients with acquired or subclonal RB1 alterations/loss (details in Supplementary Table S1) and a subset with unusual patterns of p16 expression (see “Results”). C, Illustration of a case with acquired RB1 mutations and loss of expression in metastatic samples. pRb-positive cells admixed with negative tumor cells in panels on the right are benign lymphocytes and stromal cells, serving as internal controls. Scale bars are 100 μm, except for the left bottom, which is 1 mm. D, RNA-seq for CDKN2A, encoding p16. Arrows indicate cases with chromothripsis of chromosome 12 and ecDNA amplification of CDK4. TPM, transcripts per million. (C, created in part with BioRender.com.)
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Multisample analysis from all temporally or spatially distinct samples obtained for each patient. A, Conservation of chromothripsis and corresponding amplifications across all samples with available data from individual patients. ^ indicates lower purity samples compared with the other sample from same patient (Supplementary Table S5); CN values in such samples may be falsely low. * indicates chromothripsis detected by WGS only, but not detected by tNGS. N/A, not available: sample without NGS or IHC. Sample numbering is chronologic (Supplementary Table S3). B, Multisample analysis showing RB1 and TP53 genomic alterations and expression of pRb, p53, and p16 by IHC, illustrating a subset of patients with acquired or subclonal RB1 alterations/loss (details in Supplementary Table S1) and a subset with unusual patterns of p16 expression (see “Results”). C, Illustration of a case with acquired RB1 mutations and loss of expression in metastatic samples. pRb-positive cells admixed with negative tumor cells in panels on the right are benign lymphocytes and stromal cells, serving as internal controls. Scale bars are 100 μm, except for the left bottom, which is 1 mm. D, RNA-seq for CDKN2A, encoding p16. Arrows indicate cases with chromothripsis of chromosome 12 and ecDNA amplification of CDK4. TPM, transcripts per million. (C, created in part with BioRender.com.)
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Figure S1. Detailed morphologic and immunohistochemical findings: Case A01. Supplementary Figure S2. Detailed morphologic and immunohistochemical findings: Case A08. Supplementary Figure S3. Detailed morphologic and immunohistochemical findings: Case A17. Supplementary Figure S4. Detailed morphologic and immunohistochemical findings: Case A20. Supplementary Figure S5. Mutational signatures in atypical SCLC (aSCLC), never-smoker SCLC with RB1–/TP53– (nsSCLC) and smoking-associated SCLC (sSCLC) analyzed by MSK-IMPACT. Supplementary Figure S6. Circos plots showing structural variants and copy number alterations across the genome from all cases with WGS. Supplementary Figure S7. Chromothripsis assessment by targeted NGS (MSK-IMPACT) versus WGS. Supplementary Figure S8. RNAseq for non-recurrently amplified (KRAS, ERBB3, KDM5A) or deleted (TGFBR2, ARID1A) genes on chromothriptic chromosomes and TERT. Supplementary Figure S9. Comparison of chromothripsis characteristics in aSCLC vs other major lung cancer types. Supplementary Figure S10. Chromothripsis architecture in all cases profiled by whole-genome sequencing. Supplementary Figure S11. Chromothripsis in multi-sample analysis and genomic alterations in samples with histotype heterogeneity. Supplementary Figure S12. Cell cycle and p53 pathway deregulation in aSCLC. Supplementary Figure S13. Expression of potential therapeutic markers in aSCLC.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Figure S1. Detailed morphologic and immunohistochemical findings: Case A01. Supplementary Figure S2. Detailed morphologic and immunohistochemical findings: Case A08. Supplementary Figure S3. Detailed morphologic and immunohistochemical findings: Case A17. Supplementary Figure S4. Detailed morphologic and immunohistochemical findings: Case A20. Supplementary Figure S5. Mutational signatures in atypical SCLC (aSCLC), never-smoker SCLC with RB1–/TP53– (nsSCLC) and smoking-associated SCLC (sSCLC) analyzed by MSK-IMPACT. Supplementary Figure S6. Circos plots showing structural variants and copy number alterations across the genome from all cases with WGS. Supplementary Figure S7. Chromothripsis assessment by targeted NGS (MSK-IMPACT) versus WGS. Supplementary Figure S8. RNAseq for non-recurrently amplified (KRAS, ERBB3, KDM5A) or deleted (TGFBR2, ARID1A) genes on chromothriptic chromosomes and TERT. Supplementary Figure S9. Comparison of chromothripsis characteristics in aSCLC vs other major lung cancer types. Supplementary Figure S10. Chromothripsis architecture in all cases profiled by whole-genome sequencing. Supplementary Figure S11. Chromothripsis in multi-sample analysis and genomic alterations in samples with histotype heterogeneity. Supplementary Figure S12. Cell cycle and p53 pathway deregulation in aSCLC. Supplementary Figure S13. Expression of potential therapeutic markers in aSCLC.